In theory, the prescription of medication compensating the deregulation of molecular pathways should lead to better treatment of cancer. However, in a multicentre phase II study in France, this approach did not render longer periods of progression-free survival. The results, published in The Lancet, raise concerns about the implementation of personalised medicine in cancer. Continue reading
Showing articles tagged with 'Personalised Medicine'
At the Dutch Medicines Days (DMD), the Galen awards have been presented. Led by a jury, these awards are presented anually to one researcher and one drug that is the most innovative and meaningful. This year’s best researcher was Tom Würdinger, PhD of the neuro-oncology group at the VUmc, Amsterdam. The award for the best drug went to Kalydeco from Vertex, a compound indicated for cystic fibrosis (CF). Continue reading
This year, the Dutch Medicines Days 2014 (DMD) were predominated by the subject of personalised medicine. Medical doctors, researchers and delegates from insurance providers and pharmaceutical companies discussed implementation and innovative treatment methods considering this subject. The DMD is a congress on innovative drug research, hosted by the Federation for Innovative Drug Research in the Netherlands (FIGON). Continue reading